Previous 10 | Next 10 |
2024-04-02 06:01:11 ET Summary Viking Therapeutics' share price has rapidly increased from recent weight loss drug excitement. The company’s value seems to be derived from its weight loss and NASH/MASH candidates. VK2735, the weight loss candidate, presents a potentiall...
2024-03-27 15:53:27 ET More on Ligand Pharmaceuticals Ligand Pharmaceuticals Inc. (LGND) Q4 2023 Earnings Call Transcript Ligand Pharmaceuticals Non-GAAP EPS of $1.05 beats by $0.39, revenue of $28.1M beats by $2.46M Ligand Pharmaceuticals Q4 2023 Earnings Preview ...
2024-03-24 00:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-03-13 22:38:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that Chief Executive Officer Todd Davis and Chief Financial Officer Tavo Espinoza will participate in a fireside chat at the Barclays 26 th Annual Global Healthcare Conference in Miami on Thursday, March 14, 2024, at 10:45 a.m...
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) has caught the attention of the investment community today with its bullish price action. The company's shares have moved 23.34% on the day to $91.79. Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or a...
Conference Call and Webcast at 8:30 a.m. Eastern Time Today Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported financial results for the three and twelve months ended December 31, 2023, and provided an operating forecast and business updates. Ligand management will ho...
First Solar Inc. (FSLR) is expected to report $3.19 for Q4 2023 VIZIO Holding Corp. Class A (VZIO) is expected to report $0.02 for Q4 2023 Henry Schein Inc. (HSIC) is expected to report $0.71 for Q4 2023 Republic Services Inc. (RSG) is expected to report $1.28 for Q4 2023 Forge Gl...
2024-02-22 17:03:07 ET More on Ligand Pharmaceuticals Johnson & Johnson posts Q4 beat as pharma and MedTech outperform FDA approves Ligand's Zelsuvmi for treatment of molluscum Seeking Alpha’s Quant Rating on Ligand Pharmaceuticals Historical earni...
Fycompa® is the 16 th Captisol-enabled™ product approved worldwide Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its partner Eisai Co., Ltd. obtained marketing authorization approval in January 2024 from the Japanese Ministry of Health, Labour a...
News, Short Squeeze, Breakout and More Instantly...
Ligand Pharmaceuticals Incorporated Company Name:
LGND Stock Symbol:
NASDAQ Market:
Gilead Sciences, Inc. (NASDAQ: GILD) announced upbeat top-line results from an interim analysis of its late-stage study PURPOSE 1. PURPOSE 1 is a p...
CAPVAXIVE is the sixth FDA-approved product to utilize the Pfenex Expression Technology® platform Ligand is entitled to a royalty on worldwide net sales of CAPVAXIVE Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that its collaborator Merck, known as...
Bristol Myers Squibb (NYSE: BMY) announced that the FDA will now decide on the biologics license application (BLA) for the subcutaneous formulation...